Trials / Completed
CompletedNCT00038428
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Telik · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLK286 |
Timeline
- Start date
- 2001-06-01
- Primary completion
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2002-05-31
- Last updated
- 2011-07-25
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00038428. Inclusion in this directory is not an endorsement.